Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hui-Ming Chen

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2015
Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body RadiotherapyHui-Ming Chen, Ge Ma, Neil Gildener-Leapman, et al.
Cancer Research|December 15, 2023
LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell TherapySunny Mai, Alan Hodges, Hui-Ming Chen, et al.
The Journal of Clinical Investigation|October 24, 2018
Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunityHui-Ming Chen, William van der Touw, Yuan Shuo Wang, et al.
Immunity|June 14, 2015
DC-SIGN(+) Macrophages Control the Induction of Transplantation TolerancePatricia Conde, Mercedes Rodriguez, William van der Touw, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2015
Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body RadiotherapyHui-Ming Chen, Ge Ma, Neil Gildener-Leapman, et al.
Cancer Research|December 15, 2023
LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell TherapySunny Mai, Alan Hodges, Hui-Ming Chen, et al.
The Journal of Clinical Investigation|October 24, 2018
Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunityHui-Ming Chen, William van der Touw, Yuan Shuo Wang, et al.
Immunity|June 14, 2015
DC-SIGN(+) Macrophages Control the Induction of Transplantation TolerancePatricia Conde, Mercedes Rodriguez, William van der Touw, et al.
Pageof 7